Evaluating the Evolving Atopic Derm Landscape

研报英文原文证据摘录

Evaluating the Evolving Atopic Derm Landscape

Phase 1/1b NCT07235384 Preclinicalleastup to weekly 150 mg/kg IV dosing. Global Phase 1/1b AD trial began in December 2025.

ex vivo AD skin-explant data showing normalization of epidermal hyperproliferation, improved

integrity, lower epidermal thickness, and reduced inflammatory-marker release. Company says TRIV-509 TRIV-509 Triveni Bio Private Dual-specific, half-lifeantibodyextended monoclonal KLK5 + KLK7 Phase 2 NCT07167758 Trivenibarrierwas superiorreports to IL-4R inhibition in multiple preclinical AD models. Clinical efficacy results are pending.

TRIV-573 Triveni Bio Private Second-generationbispecifichalf-life extended KLK5/7 blockadeinhibition + IL-13 Phaseconcept1; Phaseplanned2 AD2Hproof-of-2026 Public trial ID notsourcesidentified in reviewed Trivenirelativesaysto KLK5/7the moleculeinhibitioncombinesplus Th2barriertargeting.repairHumanand anti-inflammatoryefficacy data are notblockade,yet public.with preclinical additivity

1/2a AD, median EASI-75 at Week 12 was 64.9% with galvokimig versus 12.3% with placebo; EASI-90 was Galvokimig versus 3.5%. Common TEAEs through Week 18 were rhinitis, nasopharyngitis, headache, dizziness, and UCB9741 / UCB Public Multispecific antibody-basedalbumin bindingtherapeutic with IL-13 + IL-17A + IL-17F Phase 2b recruiting NCT04643457; NCT07277660 In46.6%oropharyngealPhase pain. UCB called the signal positive and convincing and advanced the program to Phase 2b.

Pfizer reported that tilrekimig met the primary endpoint; placebo-adjusted Week-16 EASI-75 rates were 38.7%,

Tilrekimig

07275315 / PF- Pfizer Public Trispecific antibody IL-4 + IL-13 + TSLP Positive Phaseplanned2; Phase 3 NCT05995964 51.9%,penalty andwas49.4%seen, andacrossconjunctivitislow/mid/highfrequencydoses.